Should I buy or sell Atara Biotherapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ATRA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATRA, but not buy additional shares or sell existing shares. View ATRA analyst ratings or view top-rated stocks .

What is Atara Biotherapeutics' stock price target for 2024?

3 brokerages have issued 12 month target prices for Atara Biotherapeutics' stock. Their ATRA share price targets range from $28.00 to $28.00. On average, they expect the company's stock price to reach $28.00 in the next year. This suggests a possible upside of 3,816.6% from the stock's current price. View analysts price targets for ATRA or view top-rated stocks among Wall Street analysts .

How have ATRA shares performed in 2024?

Atara Biotherapeutics' stock was trading at $0.5128 on January 1st, 2024. Since then, ATRA shares have increased by 39.4% and is now trading at $0.7149. View the best growth stocks for 2024 here .

When is Atara Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our ATRA earnings forecast .

How were Atara Biotherapeutics' earnings last quarter?

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) announced its earnings results on Wednesday, November, 1st. The biotechnology company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.03. The biotechnology company earned $2.14 million during the quarter, compared to the consensus estimate of $2.20 million. Atara Biotherapeutics had a negative net margin of 3,220.88% and a negative trailing twelve-month return on equity of 783.31%.

What is Pascal Touchon's approval rating as Atara Biotherapeutics' CEO?

38 employees have rated Atara Biotherapeutics Chief Executive Officer Pascal Touchon on Glassdoor.com . Pascal Touchon has an approval rating of 60% among the company's employees. This puts Pascal Touchon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 88.0% of employees surveyed would recommend working at Atara Biotherapeutics to a friend.

What other stocks do shareholders of Atara Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include CRISPR Therapeutics (CRSP) , AbbVie (ABBV) , Exelixis (EXEL) , Dynavax Technologies (DVAX) , Sorrento Therapeutics (SRNE) , Advanced Micro Devices (AMD) , OPKO Health (OPK) , Gilead Sciences (GILD) , Micron Technology (MU) and Pfizer (PFE) .

How do I buy shares of Atara Biotherapeutics?

Shares of ATRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ATRA

Atara Biotherapeutics (ATRA) Stock Price, News & Analysis

→ Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad)

Free ATRA Stock Alerts

$0.71

+0.03 (+4.38%)

(As of 04/17/2024 ET)

Compare

Today's Range: $0.68
▼
$0.73
50-Day Range: $0.60
▼
$0.84
52-Week Range: $0.20
▼
$3.08

Volume: 832,144 shs
Average Volume: 2.81 million shs
Market Capitalization: $85.33 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $28.00

Get Atara Biotherapeutics alerts:

Atara Biotherapeutics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 3,816.6% Upside
$28.00 Price Target
Short Interest: Bearish
9.41% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.87
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$25,625 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.30) to ($0.31) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.50 out of 5 stars

Medical Sector

171st out of 914 stocks

Biological Products, Except Diagnostic Industry

18th out of 138 stocks

3.0

Analyst's Opinion

Consensus Rating
Atara Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Atara Biotherapeutics has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
9.41% of the outstanding shares of Atara Biotherapeutics have been sold short.
Short Interest Ratio / Days to Cover
Atara Biotherapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Atara Biotherapeutics has recently increased by 1.81%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Atara Biotherapeutics does not currently pay a dividend.
Dividend Growth
Atara Biotherapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Atara Biotherapeutics has received a 75.69% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Atara Biotherapeutics is -0.87.

1.1

News and Social Media Coverage

Search Interest
14 people have searched for ATRA on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.
MarketBeat Follows
9 people have added Atara Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Atara Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $25,625.00 in company stock.
Percentage Held by Insiders
Only 4.50% of the stock of Atara Biotherapeutics is held by insiders.
Percentage Held by Institutions
70.90% of the stock of Atara Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Atara Biotherapeutics are expected to grow in the coming year, from ($1.30) to ($0.31) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Atara Biotherapeutics is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Atara Biotherapeutics is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Darwin

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

Click here to download your report

About Atara Biotherapeutics Stock (NASDAQ:ATRA)

Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.

ATRA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ATRA Stock News Headlines

April 7, 2024 | americanbankingnews.com

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Average Recommendation of "Hold" by Brokerages

April 5, 2024 | businesswire.com

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 17, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

April 1, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (ATRA) and Embecta Corporation (EMBC)

March 28, 2024 | investorplace.com

ATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q4 2023

March 28, 2024 | benzinga.com

Atara Biotherapeutics: Q4 Earnings Insights

March 28, 2024 | finance.yahoo.com

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress

March 16, 2024 | finance.yahoo.com

ATRA Apr 2024 0.500 call

April 17, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

February 29, 2024 | msn.com

FDA clears Atara to begin Phase 1 study for lupus nephritis drug

February 29, 2024 | marketwatch.com

Atara Biotherapeutics Gets FDA Clearance for ATA3219 IND Application

February 29, 2024 | finance.yahoo.com

Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy

February 28, 2024 | finance.yahoo.com

Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference

February 14, 2024 | finance.yahoo.com

Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

February 14, 2024 | businesswire.com

Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

February 9, 2024 | uk.investing.com

Atara Biotherapeutics Inc (ATRA)

February 6, 2024 | uk.finance.yahoo.com

Atara Biotherapeutics, Inc. (0HIY.L)

February 5, 2024 | seekingalpha.com

Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway

February 3, 2024 | finance.yahoo.com

After losing 76% in the past year, Atara Biotherapeutics, Inc. (NASDAQ:ATRA) institutional owners must be relieved by the recent gain

January 11, 2024 | finance.yahoo.com

Seth Klarman's Firm Exits Atara Biotherapeutics Inc Holding

January 11, 2024 | finance.yahoo.com

Seth Klarman's Exit from Atara Biotherapeutics Inc

January 9, 2024 | businesswire.com

Tab-cel BLA on Track for Submission in Q2 2024 Following Positive New Data from Pivotal ALLELE Study

January 8, 2024 | msn.com

Atara to conduct $15M registered direct offering

January 8, 2024 | finance.yahoo.com

Atara Biotherapeutics Announces $15 Million Registered Direct Offering

January 8, 2024 | finance.yahoo.com

Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference

January 4, 2024 | finance.yahoo.com

Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 20, 2023 | finance.yahoo.com

Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories

See More Headlines

Receive ATRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/01/2023
Today: 4/17/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:ATRA
CUSIP: N/A
CIK: 1604464
Web: www.atarabio.com
Phone: (805) 623-4211
Fax: N/A
Employees: 334
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $28.00
High Stock Price Target: $28.00
Low Stock Price Target: $28.00
Potential Upside/Downside: +3,900.0%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.62)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-276,130,000.00
Net Margins: -3,220.88%
Pretax Margin: -3,220.71%
Return on Equity: -783.31%
Return on Assets: -122.34%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.72
Quick Ratio: 0.65

Sales & Book Value

Annual Sales: $8.57 million
Price / Sales: 9.75
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.97) per share
Price / Book: -0.72

Miscellaneous

Outstanding Shares: 119,360,000
Free Float: 113,988,000
Market Cap: $83.55 million
Optionable: Optionable
Beta: 0.69

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Pascal Touchon D.V.M. (Age 61)
President, CEO & Director
Comp: $1.08M
Mr. K. Amar Murugan (Age 48)
Executive VP & Chief Legal Officer
Comp: $618.52k
Mr. Eric Hyllengren (Age 48)
Executive VP & Chief Financial Officer
Dr. Anhco Nguyen Ph.D. (Age 51)
Executive VP and Chief Scientific & Technical Officer
Alex Chapman
Vice President of Corporate Communications & Investor Relations
Ms. Jill Henrich (Age 61)
Executive VP and Global Head of Regulatory Affairs & Quality
Mr. Dan Maziasz
Executive VP & Chief Business Officer
Ms. Rajani Dinavahi M.D.
Senior VP & Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ATRA Stock Analysis - Frequently Asked Questions

Should I buy or sell Atara Biotherapeutics stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ATRA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATRA, but not buy additional shares or sell existing shares.
View ATRA analyst ratings or view top-rated stocks.
What is Atara Biotherapeutics' stock price target for 2024?: 3 brokerages have issued 12 month target prices for Atara Biotherapeutics' stock. Their ATRA share price targets range from $28.00 to $28.00. On average, they expect the company's stock price to reach $28.00 in the next year. This suggests a possible upside of 3,816.6% from the stock's current price.
View analysts price targets for ATRA or view top-rated stocks among Wall Street analysts.
How have ATRA shares performed in 2024?: Atara Biotherapeutics' stock was trading at $0.5128 on January 1st, 2024. Since then, ATRA shares have increased by 39.4% and is now trading at $0.7149.
View the best growth stocks for 2024 here.
When is Atara Biotherapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our ATRA earnings forecast.

How were Atara Biotherapeutics' earnings last quarter?: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) announced its earnings results on Wednesday, November, 1st. The biotechnology company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.03. The biotechnology company earned $2.14 million during the quarter, compared to the consensus estimate of $2.20 million. Atara Biotherapeutics had a negative net margin of 3,220.88% and a negative trailing twelve-month return on equity of 783.31%.
What is Pascal Touchon's approval rating as Atara Biotherapeutics' CEO?: 38 employees have rated Atara Biotherapeutics Chief Executive Officer Pascal Touchon on Glassdoor.com. Pascal Touchon has an approval rating of 60% among the company's employees. This puts Pascal Touchon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 88.0% of employees surveyed would recommend working at Atara Biotherapeutics to a friend.
What other stocks do shareholders of Atara Biotherapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include CRISPR Therapeutics (CRSP), AbbVie (ABBV), Exelixis (EXEL), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), OPKO Health (OPK), Gilead Sciences (GILD), Micron Technology (MU) and Pfizer (PFE).
How do I buy shares of Atara Biotherapeutics?: Shares of ATRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ATRA) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Atara Biotherapeutics (ATRA) Stock Price, News & Analysis

Atara Biotherapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Atara Biotherapeutics Stock (NASDAQ:ATRA)

ATRA Stock Price History

ATRA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ATRA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™